Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study

Drug and Alcohol Dependence

Volumn 107, Issue 2-3, 2010, Pages 221-229

  Gueorguieva, Ralitza ^a   Wu, Ran ^b   Donovan, Dennis ^c   Rounsaville, Bruce J ^b   Couper, David ^d   Krystal, John H ^b,e   O'Malley, Stephanie S ^b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Acamprosate; Alcohol research; Clinical trial; Combined behavioral intervention; Naltrexone; Trajectory based analysis

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO;

ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COMBINED BEHAVIORAL INTERVENTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRINKING BEHAVIOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; SELF REPORT; UNITED STATES;

ADULT; ALCOHOL DETERRENTS; ALCOHOL DRINKING; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAURINE; TREATMENT OUTCOME; UNITED STATES;

EID: 77649238200     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.10.017     Document Type: Article

References (63)

1. Anton R.F., Drobes D.J., Voronin K., Durazo-Avizu R., Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology 2004, 173(1-2):32-40.
2. Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., Dias J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo controlled-placebo trial. Am. J. Psychiatry 1999, 156:1758-1765.
3. Anton R.F., O'Malley S.S., Ciraulo D., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 2006, 295:2003-2017.
4. Babor T.F., Longabaugh R., Zweben A., Fuller R.K., Stout R.L., Anton R.F., Randall C.L. Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. J. Stud. Alcohol. Suppl. 1994, 12:101-111.
5. Baros A.M., Latham P.K., Monk D.H., Voronin K. What role does measuring medication compliance play in evaluating the efficacy of naltrexone?. Alcohol Carroll. Clin. Exp. 2007, 31:596-603.
6. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., Rounsaville B.J. Efficacy of disulfiram and cognitive-behavioral therapy in cocaine-dependent outpatients: a randomized placebo controlled trial. Arch. Gen. Psychiatry 2004, 64:264-272.
7. Carroll K.M., Rounsaville B.J., Nich C., Gordon L.T., Wirtz P.W., Gawin F.H. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psychotherapy effects. Arch. Gen. Psychiatry 1994, 51:989-997.
8. Chassin L., Pitts S.C., Prost J. Binge drinking trajectories from adolescence to emerging adulthood in a high risk sample: predictors and substance abuse outcomes. J. Consult. Clin. Psychol. 2002, 70(1):67-78.
9. Chung T., Maisto S.A., Cornelius J.R., Martin C.S. Adolescents' alcohol and drug use trajectories in the year following treatment. J. Stud. Alcohol. 2004, 65(1):105-114.
10. Chung T., Maisto S.A., Cornelius J.R., Martin C.S., Jackson K.M. Joint trajectory analysis of treated adolescents' alcohol use and symptoms over 1 year. Addict. Behav. 2005, 30(9):1690-1701.
11. Cramer J., Rosenheck R., Kirk G., Krol W., Krystal J. Compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003, 6:566-573.
12. Dearing R.L., Barrick C., Dermen K.H., Wlitzer K.S. Indicators of client engagement: influences on alcohol treatment satisfaction and outcomes. Psychol. Addict. Behav. 2005, 19(1):71-78.
13. Del Boca F.K., Darkes J., Greenbaum P.E., Goldman M.S. Up close and personal: temporal variability in the drinking of individual college students during their first year. J. Consult. Clin. Psychol. 2003, 72(2):155-164.
14. Diggle P.J. Analysis of Longitudinal Data 1994, Clarendon Press, Oxford.
15. Dolan C.V., Schmittman V.R., Lubke G.H., Neale M.C. Regime switching in the latent growth curve mixture model. Struct. Eq. Model. 2005, 12(1):94-120.
16. Feeney G.F., Connor J.P., Young R.M., Tucker J., McPherson A. Combined acamprosate and naltrexone, with cognitive behavioral therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol. Alcohol. 2006, 41:321-327.
17. Finney J.W., Moyer A., Swearingen C.E. Outcome variables and their assessment in alcohol treatment studies: 1968-1998. Alcohol Clin. Exp. Res. 2003, 27(10):1671-1679.
18. Fleming M.F., Barry K.L., Manwell L.B., Johnson K., London R. Brief physician advice for problem alcohol drinkers. A randomised control trial in community-based primary care practices. JAMA 1997, 277:1039-1045.
19. Fuller R.K., Branchey L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., James K.E., Lacoursiere R.B., Lee K.K., Lowenstam I., Maany I., Neiderhiser D., Nocks J.J., Shaw S. Disulfiram treatment of alcoholism. A veterans administration cooperative study. JAMA 1986, 256:1449-1455.
20. Greenbaum P.E., Del Boca F.K., Darkes J., Wang C.P., Goldman M.S. Variation in the drinking trajectories of freshmen college students. J. Consult. Clin. Psychol. 2004, 73(2):229-238.
21. Gueorguieva R., Wu R., Pittman B., Cramer J., Rosenheck R., O'Malley S., Krystal J. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol. Psychiatry 2007, 61:1290-1295.
22. Hill K.G., White H.R., Chung I.J., Hawkins J.D., Catalano R.F. Early adult outcomes of adolescent binge drinking: person and variable-centered analyses of binge drinking trajectories. Alcohol. Clin. Exp. Res. 2000, 24(6):892-901.
23. Hyytia P., Sinclair J.D. Responding for oral ethanol after naloxone treatment by alcohol-preferring AA rats. Alcohol. Clin. Exp. Res. 1993, 17(3):631-636.
24. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., Javors M.A., Ma J.Z. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003, 361:1677-1685.
25. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., McKay A., Ait-Daoud N., Anton R.F., Ciraulo D.A., Kranzler H.R., Mann K., O'Malley S.S., Swift R.M. Topiramate for treating alcohol dependence: a multi-site randomized controlled trial. JAMA 2007, 298:1641-1651.
26. Jones B., Nagin D.S., Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol. Methods Res. 2001, 29(3):374-393.
27. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P., Holzbach R., Kampf P., Stracke R., Baehr M., Naber D., Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2003, 60:92-99.
28. King A.C., Volpicelli J.R., Frazer A., O'Brien C.P. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl.) 1997, 129(1):15-22.
29. Kranzler H.R., Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol. Clin. Exp. Res. 2001, 25(9):1335-1341.
30. Krishnan-Sarin S., Krystal J.H., Shi J., Pittman B., O'Malley S.S. Family history of alcoholism influences naltrexone-induced reductions in drinking. Biol. Psychiatry 2007, 62(6):694-697.
31. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., Rosenheck R.A. Naltrexone in the treatment of alcohol dependence. NEJM 2001, 345:1734-1739.
32. Lindsey J.K. Models for Repeated Measurements 1993, Clarendon Press, Oxford.
33. Longabaugh, R., Zweben, A., LoCastro, J., WR, M., 2005. Origins, issues and options in the development of the Combined Behavioral Intervention. Journal of Studies on Alcohol 2005, 179-185.
34. Longford N.T. Random Coefficient Models 1993, Claredon Press, Oxford.
35. Mann K., Lehart P., Morgan M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol.: Clin. Exp. Res. 2004, 28(1):51-63.
36. Mason B.J. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J. Clin. Psychiatry 2001, 62(20):42-48.
37. Mason B.J. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J. Stud. Alcohol. 2005, 66(Suppl. 15):148-156.
38. Combined Behavioral Intervention Manual: A Clinical Research Guide for Therapists Treating People with Alcohol Abuse and Dependence 2004, vol. 1. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD.
39. Muthén B.O., Muthén L.K. Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcohol. Clin. Exp. Res. 2000, 24(6):882-891.
40. Muthén B.O., Muthén L.K. The development of heavy drinking and alcohol-related problems from ages 18 to 37 in a U.S. national sample. J. Stud. Alcohol. 2000, 290-300.
41. Muthén B.O. Mplus Technical Appendices 2004, Muthén & Muthén, Los Angeles, CA, (Appendix 8).
42. Nagin D.S. Analyzing developmental trajectories: a semiparametric, group-based approach. Psychol. Methods 1999, 4(2):139-157.
43. Nagin D.S., Tremblay R.E. Analyzing developmental trajectories of distinct but related behaviors: a group-based method. Psychol. Methods 2001, 6(1):18-34.
44. O'Malley S.S., Jaffe A.J., Rode S., Rounsaville B.J. Experience of a " slip" among alcoholics treated with naltrexone or placebo. Am. J. Psychiatry 1996, 153(2):281-283.
45. O'Malley S.S., Rounsaville B.J., Farren C., Namkoong K., Wu R., Robinson J., O'Connor P.G. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch. Intern. Med. 2003, 163(14):1695-1704.
46. O'Malley S., Sinha R., Grilo C.M., Capone C., Farren C.K., McKee S.A., Rounsaville B., Wu R. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol dependent women: a randomized, double-blind, placebo controlled trial. Alcohol.: Clin. Exp. Res. 2007, 31(4):625-634.
47. Pettinati H.M., O'Brien C.P., Rabinowitz A.R., Wortman S.P., Oslin D.W., Kampman K.M., Dackis C.A. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J. Clin. Psychopharmacol. 2006, 26(6):610-625.
48. Pettinati H.M., Weiss R.D., Dundon W., Miller W.R., Donovan D., Ernst D.B., Rounsaville B.J. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J. Stud. Alcohol. 2005, 15:170-178.
49. Pettinati H.M., Weiss R.D., Miller W.R., Donovan D.M., Ernst D.B., Rounsaville B.J. Medical Management (MM) Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence 2004, vol. 2. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD.
50. Project MATCH Research Group Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J. Stud. Alcohol. 1997, 58:7-29.
51. Project MATCH Research Group Project MATCH secondary a priori hypotheses. Addiction 1997, 92:1671-1698.
52. Raudenbush S.W., Bryk A.S. Hierarchical Linear Models: Applications and Data Analysis Methods 2002, Sage, Newbury Park, CA. 2nd edition.
53. Sinclair J.D. Drugs to decrease alcohol drinking. Annals Int. Med. 1990, 22:357-362.
54. Sobell L.C., Sobell M.B. Timeline follow-back: a technique for assessing self-reported ethanol consumption. Measuring Alcohol Consumption: Psycosocial and Biological Methods 1992, Human Press, New Jersey. J. Allen, R.Z. Litten (Eds.).
55. Sobell L.C., Sobell M.B. Alcohol consumption measures. Assessing Alcohol Problems: A Guide for Clinician and Researchers 1995, 55-73. National Institute on Alcohol Abuse and Alcoholism, Rockville, MD. J.P. Allen, M. Columbus (Eds.).
56. Soyka M., Preuss U., Schuetz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. Drugs RD 2002, 3(1):1-12.
57. Srisurapanont M., Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. 2005, 8(2):267-280.
58. Swift R.M., Whelihan W., Kuznetsov O., Buongiorno G., Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am. J. Psychiatry 1994, 151(10):1463-1467.
59. Volpicelli J.R., Watson N.T., King A.C., Sherman C.E., O'Brien C.P. Effect of naltrexone on alcohol " high" in alcoholics. Am. J. Psychiatry 1995, 152(4):613-615.
60. Volpicelli J.R., Rhimes K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., O'Brien C.P. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry 1997, 54:737-742.
61. Wang S.J., Winchell C.J., McCormick S., Nevius E., O'Neill R.T. Short of complete abstinence: an analysis exploration of multiple drinking episodes in alcoholism treatment trials. Alcohol. Clin. Exp. Res. 2002, 26:1803-1809.
62. Witkiewitz K., van der Maas H.J., Hufford M.R., Marlatt G.A. Non-normality and divergence in post treatment alcohol use: re-examining the Project MATCH Data " Another Way" J. Abnormal Psychol. 2007, 116(2):378-394.
63. Zweben A., Pettinati H.M., Weiss R.D., Youngblood M., Cox C.E., Mattson M.E., Gorrochurn P., Ciraulo D. Relationship between medication adherence and treatment outcomes: the COMBINE study. Alcohol.: Clin. Exp. Res. 2008, 32(9):1661-1669.